[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-404847-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-404847-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","high-acceptability-of-long-acting-injectable-prep-and-art-among-msm-and-pwid-in-india-study-report","HIGH ACCEPTABILITY OF LONG-ACTING INJECTABLE PrEP AND ART AMONG MSM AND PWID IN INDIA - Study report","","Long-acting injectable pre-exposure prophylaxis (LA-PrEP) and long-acting antiretroviral therapy (LA-ART) are evaluated for acceptability among men who have sex with men (MSM) and people who inject drugs (PWID) in India. Respondent-driven sampling recruited community-based samples across multiple sites (Nov 2022–Jan 2024), using interviewer-administered surveys and blood draws. High willingness was observed, yet vulnerable subgroups may need tailored prevention and treatment implementation. Reasons for unwillingness included cost, injection-related side effects, and concerns about effectiveness.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/high-acceptability-of-long-acting-injectable-prep-and-art-among-msm-and-pwid-in-india-study-report/404847/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/high-acceptability-of-long-acting-injectable-prep-and-art-among-msm-and-pwid-in-india-study-report/404847.png","ImageObject",300,407,{"name":42,"@type":43},"acoobca","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-27",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study objective regarding LA-PrEP and LA-ART?","Question",{"text":63,"@type":64},"To characterize acceptability and identify correlates of LA-PrEP and LA-ART among community-based samples of MSM and PWID in India.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were participants recruited and what measurements were used?",{"text":68,"@type":64},"Participants were recruited using respondent-driven sampling across designated PWID and MSM sites, followed by interviewer-administered surveys and blood draw procedures.",{"name":70,"@type":61,"acceptedAnswer":71},"What reasons were most commonly reported for unwillingness to use LA-PrEP?",{"text":72,"@type":64},"Common reasons included cost, injection-related side effects (excluding pain), disruption to diet or sleep, and concern that injections would not work.",{"name":74,"@type":61,"acceptedAnswer":75},"What did the study conclude about willingness to use long-acting injectable modalities?",{"text":76,"@type":64},"The study concluded that willingness to use long-acting injectable PrEP and ART was high among PWID and MSM in India, while emphasizing the need for further exploration of implementation strategies, especially in low-resource settings.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},404847,1791082378,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,113,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":111,"slug":112},40,"healthcare",{"id":114,"doc_module":4,"doc_module_name":25,"category_name":115,"show_sort_weight":116,"slug":117},8,"Research & Report",30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":22,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":30,"preview_page_count":4},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","HIGH ACCEPTABILITY OF LONG-ACTING INJECTABLE PrEP AND ART AMONG MSM AND PWID IN INDIA  1243   \nAllison M. McFall 1 , Talia A. Loeb 1 , Jiban J. Baishya2 , Ashwini Kedar3 , Archit Sinha 3 , Aylur K. Srikrishnan4 , Sunil S. Solomon 1 , Gregory M. Lucas 1 , Shruti H. Mehta 1  \n1 Johns Hopkins University, Baltimore, MD, USA; 2 Johns Hopkins University, New Delhi, India, 3YR Gaitonde Centre for AIDS Research and Education, New Delhi, India, 4YR Gaitonde Centre for AIDS Research and Education, Chennai, India  \nBACKGROUND  \n• Long-acting injectable pre-exposure prophylaxis (LA-PrEP) and antiretroviral therapy (LA-ART) hold significant potential to overcome challenges of daily adherence to oral modalities  \n• Population-level impact of LA-PrEP and ART requires acceptability and uptake among those with a high burden of HIV such as people who inject drugs (PWID) and men who have sex with men (MSM)  \nOBJECTIVE  \n• To characterize acceptability and correlates of LA-PrEP and LA-ART among community-based samples of MSMand PWID in India  \nMETHODS  \n• Respondent-driven sampling (RDS) of PWID and MSMacross 5 PWID sites and 2 MSM sites (750/site) Nov 2022-Jan 2024  \n• Inclusion criteria: 1) ≥18 years old and 2) injection drug use in the prior 2 years (PWID) OR 2) sex with a man in prior year (MSM)  \n• Interviewer administered survey and blood draw  \n• LA-PrEP questions for those with no prior HIV diagnosis and LA-ART questions for those with a prior diagnosis  \n• Acceptability and reasons for unwillingness to use LAPrEP/ART summarized  \n• Correlates of willingness explored using multilevel multivariable logistic regression models  \nRESULTS  \n\n| Table 1 Population characteristics |  |  |\n| --- | --- | --- |\n| n (%) or median (interquartile range) | PWID (N=3750) | MSM (N=1499) |\n| Age (years) | 28 (24 – 33) | 28 (24 – 37) |\n| Male sex | 3641 (97) | 1499 (100) |\n| Recent daily injection drug use | 2404 (58) | 0 |\n| Recent sharing needles/syringes | 1789 (50) | 0 |\n| Recent unprotected sex* | 1251 (30) | 452 (41) |\n| Previously heard of PrEP | 196 (5) | 287 (21) |\n| Living with HIV | 1310 (40) | 283 (21) |\n| Diagnosed | 583 (37) | 189 (68) |\n| Currently on antiretroviral therapy (ART) | 473 (29) | 180 (65) |\n| HIV viral load>150 copies/mL | 413 (66) | 69 (25) |\n| *Partner of any gender for PWID; anal sex with man/transgender person for MSM; Recent=in prior 6 months |  |  |\n\nHigh interest in LA-PrEP and LA-ART among key populations – however, vulnerable subgroups may require other prevention and treatment  \napproaches  \nFigure 1 Willingness to use LA-PrEP Figure 2 Willingness to use LA-ART  \nFigure 3 Correlates * of willingness to Figure 3 Correlates * of willingness to  \nuse LA-PrEP  \nRef. 18-25 yrs  \n26-35 yrs 36-45 yrs 46+ yrs  \nFemale sex  \nCurrently married Homeless  \nDaily drug injection Shared needles Hazardous drinking  \nRef. no sexual 1 partner partners 2+ partners Unprotected sex  \nRef. 18-25 yrs  \n26-35 yrs 36-45 yrs 46+ yrs  \nCurrently married Hazardous drinking  \nRef. no sexual partners  \n1 partner 2-5 partners 6-15 partners 16+ partners  \nUnprotected anal sex  \n| Table 2 Reasons for unwillingness to use LA-PrEP |  |  |\n| --- | --- | --- |\n| n (%) | PWID (N=440) | MSM (N=487) |\n| Side effects (excluding pain) from injections | 110 (31) | 92 (24) |\n| Cost | 82 (22) | 205 (42) |\n| Diet or sleep might be interrupted | 114 (30) | 53 (13) |\n| I am not at risk for HIV | 128 (26) | 43 (9) |\n| Worry injections won’t work | 108 (26) | 67 (15) |\n| It is a hassle to get injections | 135 (23) | 40 (11) |\n| Drug resistance might develop | 68 (14) | 53 (14) |\n| I do not like taking injections | 56 (12) | 50 (10) |\n\n\n| Table 3 Reasons for unwillingness to use LA-ART |  |  |\n| --- | --- | --- |\n| n (%) | PWID (N=62) | MSM (N=18) |\n| Worry injections won’t work | 21 (44) | 6 (35) |\n| Side effects (excluding pain) from injections | 19 (29) | 8 (43) |\n| It is a hassle to get injections | 15 (21) | 5 (21) |\n| Pain from the injection | 12 (15) | 10 (54) |\n","cbCaitFphpgUMzv0","https://ap.wps.com/l/cbCaitFphpgUMzv0","pdf",202198,"English","# Background\n## Objective\n## Methods\n## Results\n## Limitations\n## Conclusions\n## Acknowledgements","[{\"question\":\"What was the study objective regarding LA-PrEP and LA-ART?\",\"answer\":\"To characterize acceptability and identify correlates of LA-PrEP and LA-ART among community-based samples of MSM and PWID in India.\"},{\"question\":\"How were participants recruited and what measurements were used?\",\"answer\":\"Participants were recruited using respondent-driven sampling across designated PWID and MSM sites, followed by interviewer-administered surveys and blood draw procedures.\"},{\"question\":\"What reasons were most commonly reported for unwillingness to use LA-PrEP?\",\"answer\":\"Common reasons included cost, injection-related side effects (excluding pain), disruption to diet or sleep, and concern that injections would not work.\"},{\"question\":\"What did the study conclude about willingness to use long-acting injectable modalities?\",\"answer\":\"The study concluded that willingness to use long-acting injectable PrEP and ART was high among PWID and MSM in India, while emphasizing the need for further exploration of implementation strategies, especially in low-resource settings.\"}]","HIGH ACCEPTABILITY OF LONG-ACTING INJECTABLE PrEP AND ART AMONG MSM AND PWID IN INDIA - Study report | PDF",1790551310]